| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 |
| Sales | 0 | 65,300 | 48,820 | 40,700 | 25,540 |
| Sales Growth | -100.00% | +33.76% | +19.95% | +59.36% | -11.66% |
| Net Income | -15,950 | 17,780 | -31,840 | -54,450 | -50,580 |
| Net Income Growth | -189.71% | +155.84% | +41.52% | -7.65% | -9.93% |
Lite Strategy Inc
(LITS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The Company is focused on the clinical development of its two lead isoflavone-based drug candidates, ME-143 and ME-344. MEI Pharma, Inc., formerly known as Marshall Edwards, Inc., is based in San Diego.
Fiscal Year End Date: 06/30